Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Kyndryl Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Kyndryl Holdings Inc trades at $11.96 (market cap $2.73B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | KD | |
|---|---|---|
Market Cap | $4.49B | $2.73B |
Sector | Health | Technology |
52-Week High | $28.06 | $43.38 |
52-Week Low | $20.06 | $10.59 |
Enterprise Value | $3.69B | $5.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Kyndryl Holdings (KD) trades at $12.39, up 1.14% on the day, with a bullish technical signal from moving averages. The company reported revenue of $15.06B for 2025, achieving a net income of $252M, marking a return to profitability after losses in prior years. Recent news includes a partnership with Microsoft for sovereignty solutions and new executive appointments, but also legal investigations into the company's disclosures following a significant stock price decline earlier in 2026.
The outlook is mixed; improving cash flow and a low EV/EBITDA of 3.19 suggest undervaluation, but recent earnings misses and legal overhangs pose risks. Analyst consensus is a 'Hold' with a $14.33 price target, implying modest upside. Key investor focus is on the Q2 2026 earnings report due August 5, 2026, for confirmation of the profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
